Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Injectable Gel Solidifies into a Therapeutic Matrix

By HospiMedica staff writers
Posted on 16 Apr 2007
A new study describes a polysaccharide-based hydrogel, designed to be injected into the spinal cord and other tissues, which forms a three-dimensional (3D) matrix that eventually disintegrates as it is replaced by healthy tissue. More...


The new material, developed by researchers at Purdue University (West Lafayette, IN; USA) and Arizona State University (ASU; Tempe, AZ, USA) mimics an extracellular matrix (ECM) environment. By attaching the polysaccharide-binding peptides (PBP) from antithrombin III to a synthetic material called polyethylene glycol, the basic hydrogel is formed. Mixing this peptide-polyethylene glycol combination with heparin--a natural polysaccharide--instantly solidifies it into a 3D matrix.

The scientists have also shown how gels are strengthened by using polymers that have more functional groups--segments that attach to other molecules to fortify the matrix by forming crosslinks from one molecule to the next. This crosslinking can be used to strengthen the matrix about 10 times, which could be compared to raising consistency of the gel from that of mayonnaise to something closer to that of cartilage. The gel can also be loaded with time-released therapeutic drugs, such as growth factors used in wound healing, bone regeneration, and other medical applications. This same approach could be used to improve drug-eluting stents, making them less prone to clot formation. The study was presented at the American Chemical Society's national meeting, held during March 2007 in Chicago (IL, USA).

"It is thought that most of the damage caused in spinal cord injury is not caused by the initial injury but by the inflammation that occurs later,” said lead author Dr. Alyssa Panitch, an associate professor of biomedical engineering at Purdue. "So, if you could inject this gel with a therapeutic agent that inhibits inflammation while secreting growth factors within several hours of injury that could potentially be very useful.”

Polysaccharide-based hydrogels have emerged as an intriguing biomaterial for tissue engineering due to their low immunologic response and the biologic importance of polysaccharides throughout the ECM in vivo. Within the ECM, polysaccharides associate with proteins to regulate cell adhesion, migration, and proliferation.


Related Links:
Purdue University
Arizona State University

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Pressure Guidewire
SavvyWire
Head Rest
Medifa 61114_3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.